SBRT showed improved LPFS over RFA in treating single recurrent small HCC, especially for tumors ≤2 cm. Both SBRT and RFA demonstrated similar PFS, OS, and safety profiles, with mild to moderate side ...

The median radiographic progression-free survival was 4.6 years in patients who received stereotactic body radiotherapy and 2.3 years in patients who did not. Adding metastasis-directed stereotactic ...

In patients with recurrent small hepatocellular carcinoma (HCC), stereotactic body radiotherapy (SBRT) demonstrated superior local progression-free survival (PFS) and tumor control at 3 years compared ...

SBRT administered to oligometastases was associated with survival benefits in phase 2 trial participants with CRPC receiving abiraterone and ADT. For patients with oligometastatic castrate-resistant ...